Oculis Holding AG
OCS20.690USD
+0.210+1.03%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
More Details of Oculis Holding AG Company
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Oculis Holding AG Info
Ticker SymbolOCS
Company nameOculis Holding AG
IPO dateMar 03, 2023
CEOSherif (Riad)
Number of employees49
Security typeOrdinary Share
Fiscal year-endMar 03
AddressBahnhofstrasse 20
CityZUG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code6300
Phone41417113960
Websitehttps://oculis.com/
Ticker SymbolOCS
IPO dateMar 03, 2023
CEOSherif (Riad)
Company Executives of Oculis Holding AG
Name
Name/Position
Position
Shareholding
Change
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Riad Sherif, M.D.
Dr. Riad Sherif, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Christina M. Ackermann
Ms. Christina M. Ackermann
Independent Director
Independent Director
--
-100.00%
Mr. Lionel Carnot
Mr. Lionel Carnot
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Martijn Kleijwegt
Mr. Martijn Kleijwegt
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Business Officer
Chief Business Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Mr. Robert K. Warner
Mr. Robert K. Warner
Independent Director
Independent Director
--
--
Mr. Arshad M. Khanani, M.D.
Mr. Arshad M. Khanani, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EQT Partners AB
10.21%
EQT Life Sciences
9.95%
Earlybird Venture Capital
4.40%
Pivotal Bioventure Partners Investment Advisor LLC
3.98%
BVCF Management, Ltd.
3.79%
Other
67.67%
Shareholders
Shareholders
Proportion
EQT Partners AB
10.21%
EQT Life Sciences
9.95%
Earlybird Venture Capital
4.40%
Pivotal Bioventure Partners Investment Advisor LLC
3.98%
BVCF Management, Ltd.
3.79%
Other
67.67%
Shareholder Types
Shareholders
Proportion
Venture Capital
23.74%
Private Equity
10.21%
Investment Advisor/Hedge Fund
3.17%
Corporation
2.96%
Individual Investor
2.75%
Investment Advisor
1.68%
Hedge Fund
0.55%
Research Firm
0.07%
Bank and Trust
0.05%
Other
54.82%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
49
16.42M
28.41%
+792.94K
2025Q2
51
19.48M
37.42%
+1.76M
2025Q1
51
19.44M
37.35%
+1.93M
2024Q4
86
15.00M
31.97%
-10.87M
2024Q3
87
16.29M
41.43%
-9.17M
2024Q2
88
16.63M
42.28%
-9.14M
2024Q1
91
16.14M
42.22%
-11.25M
2023Q4
93
17.20M
46.87%
-6.97M
2023Q3
92
16.51M
48.34%
-4.37M
2023Q2
91
16.72M
48.91%
-4.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EQT Life Sciences
5.75M
10.99%
+425.53K
+7.99%
Dec 31, 2024
Earlybird Venture Capital
2.54M
4.86%
+2.54M
--
Dec 31, 2024
Pivotal Bioventure Partners Investment Advisor LLC
2.30M
4.4%
--
--
Jun 30, 2025
BVCF Management, Ltd.
2.19M
4.19%
+121.79K
+5.88%
Nov 27, 2024
abrdn Inc.
1.25M
2.39%
--
--
Jun 30, 2025
Sherif (Riad M.D.)
644.75K
1.23%
-233.73K
-26.61%
Dec 31, 2024
Stefnir hf.
540.50K
1.03%
--
--
Aug 31, 2025
Nan Fung Life Sciences
514.70K
0.98%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Simplify Propel Opportunities ETF
2.81%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.12%
Even Herd Long Short ETF
0%
Simplify Propel Opportunities ETF
Proportion2.81%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.12%
Even Herd Long Short ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Oculis Holding AG?
The top five shareholders of Oculis Holding AG are:
EQT Life Sciences holds 5.75M shares, accounting for 10.99% of the total shares.
Earlybird Venture Capital holds 2.54M shares, accounting for 4.86% of the total shares.
Pivotal Bioventure Partners Investment Advisor LLC holds 2.30M shares, accounting for 4.40% of the total shares.
BVCF Management, Ltd. holds 2.19M shares, accounting for 4.19% of the total shares.
abrdn Inc. holds 1.25M shares, accounting for 2.39% of the total shares.
EQT Life Sciences holds 5.75M shares, accounting for 10.99% of the total shares.
Earlybird Venture Capital holds 2.54M shares, accounting for 4.86% of the total shares.
Pivotal Bioventure Partners Investment Advisor LLC holds 2.30M shares, accounting for 4.40% of the total shares.
BVCF Management, Ltd. holds 2.19M shares, accounting for 4.19% of the total shares.
abrdn Inc. holds 1.25M shares, accounting for 2.39% of the total shares.
What are the top three shareholder types of Oculis Holding AG?
The top three shareholder types of Oculis Holding AG are:
EQT Partners AB
EQT Life Sciences
Earlybird Venture Capital
EQT Partners AB
EQT Life Sciences
Earlybird Venture Capital
How many institutions hold shares of Oculis Holding AG (OCS)?
As of 2025Q3, 49 institutions hold shares of Oculis Holding AG, with a combined market value of approximately 16.42M, accounting for 28.41% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.01%.
What is the biggest source of revenue for Oculis Holding AG?
In --, the -- business generated the highest revenue for Oculis Holding AG, amounting to -- and accounting for --% of total revenue.
